Press release
TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Download DelveInsight's comprehensive Transforming Growth Factor Beta Inhibitors Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Transforming Growth Factor Beta Inhibitors Pipeline Outlook Report [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Transforming Growth Factor Beta Inhibitors Pipeline Report
* DelveInsight's Transforming Growth Factor Beta Inhibitors pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Transforming Growth Factor Beta Inhibitors treatment.
* The leading Transforming Growth Factor Beta Inhibitors Companies such as Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
* Promising Transforming Growth Factor Beta Inhibitors Therapies such as Trabedersen, KER-050, STP705 , and others.
Access DelveInsight's in-depth Transforming Growth Factor Beta Inhibitors Pipeline Analysis for a closer look at promising breakthroughs @ Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Transforming Growth Factor Beta Inhibitors Emerging Drugs Profile
* Trabedersen: Oncotelic
Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-2 messenger RNA. Ready for registration trials--Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.
* KER-050: Keros Therapeutics
KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF- receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF- family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.
* STP705: Sirnaomics
STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.
Get a detailed analysis of the latest innovations in the Transforming Growth Factor Beta Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ Transforming Growth Factor Beta Inhibitors Unmet Needs [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Transforming Growth Factor Beta Inhibitors Companies
Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company , and others.
Transforming Growth Factor Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
Transforming Growth Factor Beta Inhibitors Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming Transforming Growth Factor Beta Inhibitors Therapies and key Transforming Growth Factor Beta Inhibitors Developments @ Transforming Growth Factor Beta Inhibitors Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Transforming Growth Factor Beta Inhibitors Pipeline Report
* Coverage- Global
* Transforming Growth Factor Beta Inhibitors Companies- Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
* Transforming Growth Factor Beta Inhibitors Therapies- Trabedersen, KER-050, STP705 , and others.
* Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive Transforming Growth Factor Beta Inhibitors Pipeline Report-access it now! @ Transforming Growth Factor Beta Inhibitors Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Transforming growth factor beta inhibitors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Transforming growth factor beta inhibitors - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Transforming growth factor beta inhibitors Collaboration Deals
* Late Stage Products (Phase III)
* Trabedersen: Oncotelic
* Mid Stage Products (Phase II)
* KER-050: Keros Therapeutics
* STP705: Sirnaomics
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Transforming growth factor beta inhibitors Key Companies
* Transforming growth factor beta inhibitors Key Products
* Transforming growth factor beta inhibitors- Unmet Needs
* Transforming growth factor beta inhibitors- Market Drivers and Barriers
* Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
* Transforming growth factor beta inhibitors Analyst Views
* Transforming growth factor beta inhibitors Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tgfb-inhibitor-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4165718 • Views: …
More Releases from ABNewswire
Hemophilia B Market Outlook 2034 - Clinical Trials, Market Size, Medication, Pre …
Hemophilia B companies include UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, Pfizer, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.
Hemophilia B Market Summary
The Hemophilia B market size in the 7MM was ~USD 3.4 billion in 2023, with the US as the largest contributor. Current treatments mainly include replacement therapy with recombinant factor IX products (e.g., BeneFIX, RIXUBIS, IXINITY, ALPROLIX,…
5-HT2 Agonist Pipeline Shows Strong Growth: 20+ Companies Advancing Clinical Dev …
DelveInsight's, "5-HT2 Agonist - Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in 5-HT2 Agonist pipeline landscape.
Advancements in precision medicine and pharmacogenomics are shaping this market by enabling selective targeting of serotonin receptor subtypes such as 5-HT2A and 5-HT2C. These innovations not only reduce side effects but also significantly improve patient safety and treatment efficacy. Personalized approaches that identify patients most likely to respond…
Embolic Protection Devices Market is expected to Sour at a CAGR of 7.58% by 2032 …
Global Embolic Protection Devices Market Set to Reach USD 1.16 Billion by 2032, Driven by Rising Cardiovascular and Neurovascular Burden and Technological Advancements
(Albany, USA) DelveInsight's, "Embolic Protection Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032, " reveals that the global embolic protection devices (EPDs) market is on a strong growth trajectory. Valued at USD 648.51 million in 2024, the market is projected to nearly double, reaching USD…
Oncolytic Virus Cancer Therapy Pipeline Outlook 2025: Clinical Trial Studies, EM …
DelveInsight's, "Oncolytic Virus Cancer Therapy Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
More Releases for Transforming
Transforming Lives , Together
Unessa Foundation is a purpose-driven organization committed to transforming lives, together. Built on the belief that unity and compassion are the cornerstones of meaningful change, Unessa empowers individuals and communities through inclusive programs, collaborative efforts, and a people-first approach.
Rooted in dignity, empathy, and impact, our mission is to uplift underrepresented voices, close opportunity gaps, and strengthen human connections that create lasting social change. At Unessa, we see every person as…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
Transforming Higher Education Admissions
Radius X, a user-friendly platform for admission automation and data analysis, is now available for higher education providers. Designed to simplify the admissions process, Radius X enhances the student experience through self-service options and automation.
Admissions teams today face growing challenges as they handle more applications and higher expectations from students. Many are overwhelmed by paperwork and manual tasks that take away valuable time. Radius X addresses these struggles by…
Curiotory: Transforming Language Learning
India's ultimate language learning app
Curiotory is a language learning platform dedicated to creating an enjoyable and effective learning experience. With a focus on online language learning, Curiotory empowers learners to achieve fluency and cultural understanding.
Curiotory, a trailblazer in the language learning industry, is proud to announce its continued commitment to providing a unique, immersive, and personalized approach to language education. With a mission to bridge cultural gaps and make…
Transforming Smiles, Transforming Lives: Introducing Dr. Robert Rifkin, the Maes …
Image: https://www.getnews.info/uploads/3cc5ecdc456666ed434d2b2f5410c024.png
Dr. Robert Rifkin, the visionary force behind some of the most iconic smiles worldwide, continues to redefine the standards of cosmetic dentistry. With over four decades of unparalleled expertise, Dr. Rifkin has earned his place as the godfather of cosmetic dentistry, revolutionizing the field with his innovative treatments and unparalleled artistry.
A Legacy of Innovation
For over 40 years, Dr. Robert Rifkin has been at the forefront of cosmetic dentistry in…
